Sector News

Evotec says Sanofi deal makes it anti-infectives powerhouse

June 18, 2018
Life sciences

It’s taken more than three months to work through the detail, but Sanofi has now signed a deal to transfer its anti-infectives unit to Evotec.

The main elements of the agreement remain unchanged form when it was announced in March. Around 100 Sanofi employees will go onto Evotec’s payroll but will stay at the its site in Lyons, and more than 10 infectious disease R&D programmes will be transferred to the German biotech. Sanofi is also stumping up €60m in initial funding and says it will provide “significant” ongoing support without specifying numbers.

The deal comes after extensive negotiations with France’s powerful unions and government officials over the job security of the French employees under their new management, and the deal includes “specific long-term commitments of employment,” according to Evotec. It’s been reported that that includes five-year employment contracts.

The aim is to inject some biotech-style nimbleness and flexibility into Sanofi’s anti-infectives portfolio, and also for the unit to become an open science focal point – bringing together other “companies, foundations, academia, and government agencies,” says Evotec. That essentially means getting other research groups to put drug candidates through Evotec’s R&D platform, and tapping into public funding sources.

For its part, Sanofi is hanging onto options to develop and commercialise any potential product candidates from its contributed projects.

Evotec’s CEO Dr Werner Lanthaler (pictured) said that the biotech will have around 180 scientists working in this area when the transaction completes in the next few weeks – subject to regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.” It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria, as well as new-mechanism antiviral drugs.

Last month, Evotec’s chief scientific officer Cord Dohrmann said that the new R&D unit will have “one of the largest infectious disease drug discovery platforms and pipelines [with] over 20 projects” mainly in antimicrobial and antiviral therapy. Sanofi’s vaccines unit wasn’t included in the deal, and most of the projects being transferred are in the discovery or preclinical stages.

For Sanofi, the spin-out reflects not only the challenging nature of anti-infectives research, but also changing priorities at the French drugmaker, which is in the midst of a major revamp of its pipeline following the acquisitions of Ablynx and Bioverativ.

By Phil Taylor

Source: PMLive

comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach